What Ypozane S Treats: Main Uses and Benefits

Ypozane S (Osaterone acetate) is used to address the symptoms and structural cause of Benign Prostatic Hypertrophy (BPH) in entire male dogs, a condition characterized by a hormonally-driven enlargement of the prostate gland. The primary indication for this product is the treatment of benign prostatic hypertrophy (BPH) in male dogs, which aligns with its therapeutic purpose.

---

Therapeutic Scope and Symptom Management

This medication is applied across domains where additional symptomatic support is needed for conditions presenting with localized discomfort in the prostate. The core therapeutic focus is applied in scenarios where additional management of discomfort is required, helping with symptom clusters that may become intense or disruptive. The key indications for which this medication is relevant involve symptoms linked to organ-specific functional stress, such as difficult urination (dysuria), the presence of urethral discharge, and defecation difficulties including straining or compressed feces.

“The treatment supports the patient during difficult episodes by easing distress and may assist with symptom management while maintaining functional stability in breeding animals.”

The primary therapeutic benefit is considered relevant for easing the overall symptom load by addressing prostate volume. This provides supportive relief when symptoms interfere with routine activities, generally contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relevant for Lower Urinary Tract Signs (LUTS).

Regulatory References

1. Treatment of benign prostatic hypertrophy (BPH) in male dogs

Who Can and Cannot Use Ypozane S? — Official Regulatory Information

This section outlines the documented eligibility and non-eligibility requirements for Ypozane S, strictly based on authoritative government regulatory documents from agencies like the European Medicines Agency (EMA).

Eligibility Scope	Official Regulatory Statement
Populations for Whom Use is Allowed	Male dogs (canine species).
Populations for Whom Use is Not Recommended	Dogs weighing less than 3 kg (No safety data are available for dogs in this weight range).
Populations for Whom Use is Contraindicated	None (The official regulatory document explicitly lists no contra-indications).
Condition-Specific Eligibility Rules	Caution is advised for use in dogs with a history of liver disease, as safety has not been thoroughly investigated in this specific population.
Pregnancy and Lactation Status	Not Applicable (The product is strictly designated for male dogs).

Resulting Eligibility Structure

Regulatory documentation defines that Ypozane S is only intended for male dogs. The profile establishes a minimum body weight threshold of 3 kg, effectively excluding very small dogs because data regarding safety and efficacy in this population are not available. The absence of a formal contraindication means that there are no absolute prohibitions of use based on specific health conditions listed in the labeling, though the drug must be used with caution in patients with a history of liver disease.

Interactions with other medicines and products

Official government regulatory documents state that no general drug-drug interactions are known for Ypozane S (Osaterone acetate). The product's interaction profile is therefore characterized primarily by the absence of known clinically significant combination risks and a focus on specific co-administration permissions, which are formally documented in the regulatory label.

---

Documented Co-administration Permissions

Substance Category	Interaction Description and Conditions
Antimicrobials	Concurrent administration is permitted when the underlying condition, benign prostatic hypertrophy (BPH), is associated with prostatitis. This is an explicit label allowance for co-use.
Food	Administration is permitted with food. There is no requirement documented in the label to separate the medicine from meals.

---

Pharmacokinetic Interaction Findings

The regulatory data includes specific findings concerning how Osaterone acetate interacts with other substances in the body. The binding of the drug to plasma proteins, primarily albumin, is formally documented as being not affected by other substances known to specifically bind to albumin. This finding supports the overall structure of a minimal interaction profile by confirming a lack of interference at this critical binding site.

No specific metabolic interactions, such as those mediated by CYP enzymes, or formal contraindications involving co-administered medicines are stated in the official regulatory prescribing information.

Blocking the Androgen Growth Signal

The core mechanism of action involves the active metabolite of osaterone acetate functioning as a competitive antagonist at the Androgen Receptor (AR), primarily within prostatic tissue. This action blocks the binding of the natural androgen Dihydrotestosterone (DHT) to the receptor, thereby suppressing the molecular signal necessary for gene transcription and subsequent prostate cell proliferation. This loss of growth stimulus results in cellular atrophy and a reduction of prostate tissue volume.

---

Dual Inhibition of DHT Production

The drug also exerts a dual influence on the local hormone environment by acting as an inhibitor of the 5-alpha reductase enzyme and limiting the cellular uptake of androgens. Inhibition of this enzyme reduces the conversion of testosterone to DHT. This dual action further reduces the local concentration of DHT within the prostate, reinforcing the receptor blockade, which contributes to the observed decrease in prostate volume.

---

Modulating Steroid Hormone Cascades

Additionally, osaterone acetate interacts with related steroid pathways, exhibiting progestogen activity and a transient glucocorticoid-like effect. This secondary action leads to a temporary suppression of the body’s cortisol production via the Hypothalamic-Pituitary-Adrenal (HPA) axis, demonstrating engagement with broad endocrine regulatory systems.

How to Use Ypozane S: Administration Guidelines

The usage of Ypozane S (Osaterone acetate) is a short-term, cyclical oral treatment based on the animal's body weight. This pattern ensures the intermittent administration of the steroidal antiandrogen.

---

Administration Scope

Entity	Details
Route of administration:	Oral use (tablets)
Dosing schedule (per kg):	The dose is calculated to deliver 0.25 to 0.5 mg osaterone acetate per kilogram of body weight, administered by selecting the appropriate tablet strength (1.875 mg, 3.75 mg, 7.5 mg, or 15 mg).
Frequency and Timing:	Administration is once daily for a fixed course of 7 consecutive days.
Timing in relation to meals:	The tablet can be given either directly into the mouth or administered with food.
Population-specific rules:	No data are available for the use of the product in animals weighing less than 3 kg.
Special procedural conditions:	The maximum dose should not be exceeded.

---

Course Duration and Re-treatment Protocol

Osaterone acetate is used in a defined 7-day course, which is not intended for continuous, long-term daily use. Following treatment, the clinical effect is observed to persist for at least five months. Consequently, re-evaluation for a second course should only occur if clinical signs recur after a minimum 5-month interval from the completion of the initial 7-day regimen. This time constraint governs the cyclical administration pattern of the medicine.

Research evidence / Overview of Studies for Ypozane S (Osaterone Acetate)

---

Evidence for Use in Benign Prostatic Hypertrophy (BPH) in Entire Male Dogs

The research base examining Osaterone acetate, the active substance in Ypozane S, was primarily developed through Randomized Controlled Clinical Field Trials and subsequent reviews of that data. These studies were applied in research contexts involving fluctuating or unstable symptoms related to benign prostatic hypertrophy (BPH). These trials used objective methods to explore how symptoms change over time in entire male dogs.

The studies examined dogs with conditions marked by functional limitations and used methods like ultrasonography to measure outcomes such as prostate volume. They also monitored clinical scores to capture outcomes describing episodic or acute changes related to difficulty with urination, difficulties with defecation, and discharge.

Studies reported how symptoms evolved in the observed populations following the administration of the study medication. Trials described patterns observed in the studies related to a measured change in the size of the prostatic gland. Furthermore, research describes changes measured in the clinical scores, indicating patterns related to the evolution of symptoms during the observation period. These findings describe group patterns observed in the studies and help contextualize how the condition evolved in the research populations.

---

Durability of Response and Follow-up Duration in Key Studies

Research exploring short-term symptom changes was used in studies observing responses over defined time intervals. The core studies focused on the observations seen after a short, defined dosing period, followed by an observation phase. Studies monitored the duration of observed response, describing the time frame during which the changes measured in the prostate volume and clinical signs were observed.

Research monitored patterns related to the return of clinical signs, which was observed in some studies after an intermediate-term period of typically five to six months. This evidence contributes to understanding symptom patterns following the initial administration, and provides limited insight into subsequent relapses.

---

Scientific Uncertainties and Research Gaps

First, the long-term patterns of response associated with repeated treatment courses are still being explored. Follow-up durations were limited in the primary regulatory studies, and there is limited information for long-term outcomes, particularly concerning the full pattern of response after multiple administrations over several years.

Second, data for certain physiological outcomes remain insufficient. For example, research provides limited insight into patterns of specific vascular changes in the prostate, such as blood flow, over extended observation periods.

Regulators and scientific bodies note that the evidence describes group patterns, and research does not determine whether an individual will respond similarly. The study results reflect the specific conditions and populations under which they were conducted. Comparative evidence against all possible alternative treatments for BPH is also limited.

Key Studies & References Ypozane, INN-osaterone acetate - European Commission (Official Product Information)

Common questions about Ypozane S (FAQ)

---

Q: How quickly does Ypozane S generally start working?

According to regulatory documents, the onset of clinical response to Ypozane S is typically observed within a period of two weeks following the start of administration. This reflects the time frame when measured effects, like changes in the prostate gland, usually begin to appear in studies.

Q: What is the longest duration of time Ypozane S is described for use in regulatory documents?

The medicine is administered for a defined short course of seven consecutive days. Following this, the administration is stopped. Regulatory guidance states that a re-treatment course should only be considered if clinical signs return after a minimum interval of five months has passed since the completion of the initial course.

Q: Is Ypozane S safe for older adults, according to the research?

Official regulatory documents classify Ypozane S as a veterinary medicinal product authorized for use only in dogs. The product is not authorized or described for use in humans, including older adults.

Q: Can Ypozane S affect mood or sleep?

Regulatory information lists transient behavioural changes as possible side effects. These can include changes such as either increased or decreased activity or the feeling of lethargy (decreased energy). These reactions are typically temporary.

Q: Are there any known interactions between Ypozane S and blood pressure medicines?

The official regulatory documentation states that no general drug-drug interactions are known for Ypozane S. Specific interactions with categories of medicines, such as blood pressure medicines, are not listed.

Q: How does the effectiveness of Ypozane S change over time?

The documented clinical response from the single 7-day course is described in regulatory sources as persisting for a period of at least five months, after which clinical signs may potentially return, indicating the effectiveness of the course is time-limited.

Q: Can Ypozane S cause long-term side effects according to the available data?

The potential adverse reactions listed in official documents are generally classified as transient, meaning they are temporary and expected to resolve. Research documents also note that data exploring the long-term patterns of response associated with repeated courses are currently limited.

Q: What happens if a person stops using Ypozane S suddenly?

Ypozane S is a veterinary medicinal product authorized only for use in dogs, not humans. The treatment is a defined course of seven days, after which administration is stopped as per the authorized protocol.

Q: Is it normal to feel tired or dizzy when first starting Ypozane S?

The regulatory documentation lists lethargy (a lack of energy or decreased activity) as an uncommon side effect. Information regarding dizziness is not explicitly noted in the common adverse reaction summaries.

Q: Is Ypozane S used for any other conditions besides the main one?

The official regulatory indication for Ypozane S is solely for the treatment of benign prostatic hypertrophy (BPH) in entire male dogs. No other conditions are listed in the product's authorized uses.

Q: Are there different strengths or dosages of Ypozane S described in the official labeling?

Yes, Ypozane S is described in the official labeling as being available in four different tablet strengths: 1.875 mg, 3.75 mg, 7.5 mg, and 15 mg.

Q: Does Ypozane S require any special monitoring or blood tests?

Regulatory warnings note that the medicine can cause a transient reduction of plasma cortisol concentration, which is part of the endocrine system. Regulatory documents note the need for appropriate monitoring in certain circumstances, such as in animals under stress or those with specific pre-existing conditions.

Q: Is Ypozane S classified as a controlled substance?

The active ingredient, osaterone acetate, is a synthetic steroid. It is not typically classified as a controlled substance under major regulatory schedules.

Q: Can Ypozane S cause weight change or appetite changes?

Increased appetite is described in regulatory documents as a very common side effect. Decreased appetite is listed, but as a very rare side effect.

Q: Is Ypozane S associated with any rare but serious side effects?

The regulatory documentation states that no reactions are explicitly classified as Serious Adverse Reactions in the primary summary. Side effects classified as very rare include changes in hair coat and decreased appetite.

Q: Are there any known interactions with vaccines and Ypozane S?

The official regulatory documentation states that no general drug-drug interactions are known for Ypozane S, and no specific warnings regarding co-administration with vaccines are listed.

Q: What types of professionals are typically described as prescribing Ypozane S?

The medicine is a veterinary product, and regulatory instructions note that the medicine requires re-evaluation by the veterinarian to determine the necessity of re-treatment.

Q: Is Ypozane S available in countries outside the US?

Yes, regulatory documents published by the European Medicines Agency (EMA) confirm the product is authorized for use in European countries.

Q: Do studies suggest Ypozane S is appropriate for people with a history of heart problems?

Official regulatory documents classify Ypozane S as a veterinary medicinal product authorized for use only in dogs. The product is not authorized or described for use in humans, regardless of their medical history.

Q: Is there a risk of dependence or withdrawal with Ypozane S?

Regulatory information does not list any risk of dependence or withdrawal in the documented side effects. The treatment is designed as a short, fixed 7-day course that is discontinued after completion.

Q: Are there any documented drug-to-drug interactions with common mental health medications?

The official regulatory documentation states that no general drug-drug interactions are known for Ypozane S. No specific interactions involving common mental health medications are listed.

Q: Can Ypozane S impact blood sugar levels?

The medicine is known to interact with endocrine pathways, including a transient glucocorticoid-like effect and reduction in plasma cortisol concentration. However, there is no direct reference to an impact on blood sugar levels in the adverse reaction summary.

Q: Is Ypozane S available in a liquid or injectable form?

Official regulatory documents specify the product is supplied for oral use only, in the form of tablets. No liquid or injectable forms are described in the official labeling.

Q: What are the general research themes being explored for Ypozane S?

Research has focused on measuring changes in prostate volume and clinical scores related to issues like difficulty with urination. Studies also track the duration of the observed response following the 7-day course.

Q: Do official sources describe Ypozane S as a preventative or a treatment medicine?

Regulatory documents consistently describe Ypozane S as a treatment for benign prostatic hypertrophy (BPH). It is not described in official sources as a preventative medicine.

Q: Does Ypozane S interact with alcohol according to the label?

The medicine is authorized only as a veterinary medicinal product. The regulatory documentation states that no general drug-drug interactions are known, and does not list any warnings regarding alcohol use.

Q: Can I use Ypozane S if I have a history of allergic reactions to other drugs?

The official contraindication is for animals with known hypersensitivity to the active ingredient, osaterone acetate, or any of the product's non-active components. Allergies to other, unrelated drugs are not listed as a contraindication.

Q: Is Ypozane S known to interact with herbal supplements?

The official regulatory documentation states that no general drug-drug interactions are known for Ypozane S. No specific warnings regarding co-administration with herbal supplements are listed.

Q: Is it described as appropriate for people with liver or kidney issues?

The product is a veterinary medicinal product not intended for human use. Regulatory warnings advise caution when the product is used in animals with a history of liver disease, as reversible enzyme elevations have been noted in clinical trials. No specific warnings regarding kidney issues are documented.

Storage and Disposal Requirements for Ypozane S

Official regulatory documentation confirms that Ypozane S (Osaterone acetate) tablets do not require any special storage conditions. The product has a stated shelf-life of 3 years when kept in its original, sealed packaging (aluminium/aluminium blister within a carton box).

Required Handling and Safety Measures

Domain	Official Requirement
Child Safety	KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.
Handling	Wash hands after administration. Women of child-bearing age should avoid contact with the product or wear disposable gloves.
Disposal	Any unused veterinary medicinal product or waste materials derived from it must be disposed of in accordance with local requirements.